These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12669044)

  • 1. India sets its sights on global health care market.
    Jayaraman KS
    Nat Med; 2003 Apr; 9(4):377. PubMed ID: 12669044
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials in India: balancing economic opportunity with the public health context.
    Dandona L
    Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189
    [No Abstract]   [Full Text] [Related]  

  • 3. Industry sponsored bias in cost effectiveness analyses.
    John-Baptiste A; Bell C
    BMJ; 2010 Oct; 341():c5350. PubMed ID: 20943724
    [No Abstract]   [Full Text] [Related]  

  • 4. India's growing clinical research sector: opportunity for global companies.
    Varawalla N
    IDrugs; 2007 Jun; 10(6):391-4. PubMed ID: 17642002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical process development - shortcut to market: an interview with Rolf Werner from Boehringer Ingelheim.
    Jungbauer A; Göbel U
    Biotechnol J; 2012 Jan; 7(1):14-6. PubMed ID: 22228694
    [No Abstract]   [Full Text] [Related]  

  • 6. India's drug tests.
    Padma TV
    Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
    [No Abstract]   [Full Text] [Related]  

  • 7. [Economic benefit and ethical challenges].
    Riska O
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1990. PubMed ID: 18800394
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials: the pitfalls of interpretation.
    Lokhandwalla Y; Dalvi B
    Issues Med Ethics; 1998 Apr; 6(2):47-8. PubMed ID: 15011700
    [No Abstract]   [Full Text] [Related]  

  • 9. Court compensates over activist delay.
    Jayaraman KS
    Nat Med; 1999 Oct; 5(10):1098. PubMed ID: 10502845
    [No Abstract]   [Full Text] [Related]  

  • 10. The economic fundamentals of the U.S. pharmaceutical market.
    Lybecker KM
    Manag Care; 2004 Jun; 13(6 Suppl):7-9; discussion 12-3, 41-2. PubMed ID: 15303519
    [No Abstract]   [Full Text] [Related]  

  • 11. Upcoming market catalysts in Q4 2009.
    Jatkoe L
    Nat Rev Drug Discov; 2009 Oct; 8(10):763. PubMed ID: 19794437
    [No Abstract]   [Full Text] [Related]  

  • 12. Conflicts of interest with the health industry.
    Dubois MY
    Pain Med; 2006; 7(5):463-5. PubMed ID: 17014609
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market.
    Hay JW; Yu WM
    Value Health; 2000; 3(3):181-5. PubMed ID: 16464182
    [No Abstract]   [Full Text] [Related]  

  • 14. Market watch: industry perspectives on personalized medicine.
    Zuckerman R; Milne CP
    Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
    [No Abstract]   [Full Text] [Related]  

  • 15. India emerges as new drug proving ground.
    Slater J
    Wall St J (East Ed); 2004 Feb; ():B1, B7. PubMed ID: 15290808
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretrovirals in India.
    Pujari S
    Issues Med Ethics; 1998 Jan; 6(1):24-5. PubMed ID: 16267924
    [No Abstract]   [Full Text] [Related]  

  • 17. Dollars & sense of the health care industry.
    Tremayne WH
    N J Med; 1998 May; 95(5):71-3. PubMed ID: 16013161
    [No Abstract]   [Full Text] [Related]  

  • 18. In vogue with venture.
    Patou G
    Nat Biotechnol; 2011 Nov; 29(11):967-9. PubMed ID: 22175076
    [No Abstract]   [Full Text] [Related]  

  • 19. Indian pharma enters the global arena.
    Singh S
    Cell; 2007 Mar; 128(5):811-4. PubMed ID: 17350563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Market incentives, human lives, and AIDS vaccines.
    Craddock S
    Soc Sci Med; 2007 Mar; 64(5):1042-56. PubMed ID: 17113203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.